CEO Executive AssistantGene therapy occupies a unique position in biopharmaceuticals: it is scientifically transformative, operationally complex, and commercially unprecedented. The possibility of single-dose cures for previously untreatable genetic diseases creates extraordinary promise - and extraordinary organizational challenges. For CEOs of gene therapy companies, the demands placed on every organizational function are at the frontier of what is technically, regulatorily, and commercially possible.
Effective delegation is not merely a management efficiency tool for gene therapy CEOs. It is the organizational design principle that determines whether a company can advance the science, navigate the regulatory environment, manufacture a complex biologic product at scale, and bring a transformative therapy to patients who have been waiting for one. This guide provides a comprehensive delegation framework for leaders of gene therapy organizations.
The Gene Therapy Organizational Landscape
Gene therapy companies face a distinctive combination of challenges that shapes the delegation imperative:
Manufacturing complexity. Viral vector production (AAV, lentiviral, adenoviral) is among the most technically demanding processes in biopharmaceuticals. Yield variability, scalability challenges, quality control requirements, and supply chain fragility require dedicated manufacturing and process development expertise that goes far beyond typical pharmaceutical operations.
Regulatory novelty. The FDA’s Center for Biologics Evaluation and Research (CBER) has developed evolving guidance for gene therapy, but many programs navigate truly unprecedented regulatory situations - requiring significant pre-submission scientific dialogue and a regulatory affairs team with deep experience in advanced therapy regulation.
Clinical complexity. Gene therapy trials involve small patient populations (often for ultra-rare diseases), novel endpoints, complex informed consent requirements reflecting the permanent nature of genetic modification, and long-term follow-up obligations that extend for years post-treatment.
Commercial model innovation. Gene therapies with transformative clinical profiles and ultra-high list prices require entirely novel commercial models: outcomes-based contracting, annuity payment arrangements, specialty pharmacy models, and payer engagement strategies without precedent in the industry.
According to McKinsey research on advanced therapy organizations, gene therapy companies that invest in dedicated functional expertise early - rather than trying to do everything with a generalist team under CEO direction - consistently advance programs more efficiently and with better outcomes.
R&D Delegation for Gene Therapy CEOs
Research and Translational Development
What to delegate:
- Vector design and optimization programs
- Animal model studies and proof-of-concept research
- Biomarker and disease natural history research
- Academic research collaboration management
- Translational research portfolio management
To whom: Chief Scientific Officer, with VP-level research directors for vector biology, gene editing platforms, and disease biology.
What the CEO retains: Platform strategy decisions, major academic collaboration or licensing decisions, and capital allocation across research programs.
Clinical Development
Gene therapy clinical development requires specialized expertise in rare disease trial design, novel endpoints, expanded access protocols, and the unique safety monitoring requirements associated with permanent genetic modification.
What to delegate:
- Clinical trial protocol development and management
- Site selection with expertise in rare disease and gene therapy administration
- Patient identification and enrollment strategy
- Independent Data Safety Monitoring Committee oversight
- Long-term follow-up study management
- Clinical pharmacology and dose-finding study design
To whom: Chief Medical Officer, with clinical program directors for each indication.
What the CEO retains: Stage gate go/no-go decisions at major program milestones, decisions about which indications to advance based on unmet need and organizational capacity, and decisions about compassionate use and expanded access policies.
Manufacturing Delegation
Manufacturing is the most distinctive and challenging delegation domain for gene therapy CEOs. Viral vector production is technically demanding, supply chain fragility is a persistent challenge, and manufacturing failures directly affect clinical trials and commercial supply.
What to delegate:
- Viral vector manufacturing operations (internal or CMO)
- Process development and scale-up programs
- Quality control testing and release
- CMO selection and oversight
- Supply chain planning and risk management
- Facility qualification and regulatory compliance
- Manufacturing technology development (next-generation vector platforms, continuous manufacturing)
To whom: Chief Technical Officer or VP of Technical Operations, with dedicated functions for process development, manufacturing operations, and quality.
What the CEO retains: Strategic decisions about manufacturing insourcing vs. CMO partnership, major facility investment decisions, and supply chain crisis management.
The gene therapy manufacturing delegation challenge is acute because manufacturing failures can directly halt clinical programs or commercial supply. The CEO must ensure robust manufacturing governance without becoming involved in operational decisions that belong to the technical team.
Regulatory Delegation
CBER regulation of gene therapies has evolved significantly and continues to evolve. Gene therapy regulatory strategy requires specialists who understand CBER’s specific guidance frameworks, pre-IND consultation processes, and the evolving requirements for long-term follow-up studies.
What to delegate:
- Pre-IND meeting preparation and management
- IND preparation, maintenance, and annual reporting
- BLA preparation and submission
- Breakthrough therapy and regenerative medicine advanced therapy (RMAT) designation management
- Advisory committee preparation
- Long-term follow-up protocol design and reporting
- International regulatory filings (EMA ATMP designation, etc.)
To whom: Chief Regulatory Officer or VP of Regulatory Affairs, with a gene therapy regulatory specialist or team.
What the CEO retains: CBER senior leadership relationship, strategic regulatory pathway decisions, and external communication on major regulatory milestones.
The pharma CEO guide provides a foundational framework for regulatory delegation that gene therapy CEOs can adapt to the CBER context.
Commercial and Payer Strategy Delegation
Gene therapy commercial strategy requires unprecedented innovation in pricing, payer contracting, and patient access. The commercial team must develop entirely new contracting models - outcomes-based arrangements, installment payment structures, indication-specific warranties - that have not been attempted in most payer markets.
What to delegate:
- Brand positioning and commercial strategy development
- Payer contracting strategy development and negotiation execution
- Specialty pharmacy program design and management
- Patient services and access program operations
- Key account management (treatment centers, academic medical centers)
- Market access analytics and health economic modeling
To whom: Chief Commercial Officer, supported by a Head of Market Access with gene therapy experience.
What the CEO retains: Major pricing decisions, outcomes-based contracting architecture (the CEO must personally understand and commit to the commercial model), investor-facing commercial narrative, and relationships with key payer leadership at the CEO level.
For additional context on commercial delegation in pharma, the pharma commercial strategy guide covers how to structure CEO commercial engagement for novel and complex product launches.
Patient Community and Advocacy Delegation
Gene therapy programs typically target rare diseases with highly organized and engaged patient communities. The CEO’s relationship with these communities is strategic and personal, but the operational relationship management belongs to the medical affairs and patient advocacy team.
What to delegate:
- Patient advocacy organization relationship management (operational)
- Patient registry partnership management
- Natural history study community engagement
- Patient advisory board facilitation
What the CEO retains: Personal relationships with the leadership of the most prominent patient advocacy organizations in the company’s disease areas, participation in patient advocacy foundation events as a visible organizational representative.
Governance Cadence for Gene Therapy CEOs
- Weekly: Direct report one-on-ones, key program status updates
- Monthly: R&D pipeline review with CMO and CSO (stage gates, enrollment, safety), manufacturing status with CTO (yield, batch success, supply risk), regulatory briefing with CRO
- Quarterly: Commercial readiness review, payer engagement update, full leadership team strategic review, board meeting
- Annually: Portfolio strategy session, manufacturing technology roadmap review, organizational design assessment
Managing the Board for Gene Therapy Companies
Gene therapy company boards often include biotech investors, patient advocates, and scientific advisors with specific gene therapy expertise. The CEO’s board management responsibilities include:
What to delegate:
- Board meeting logistics and materials preparation support
- Board committee support (audit, compensation, science and technology)
What the CEO retains: Board communication, relationship with Board Chair, board meeting facilitation, and presentation of scientific, regulatory, manufacturing, and commercial strategy.
Common Gene Therapy Delegation Failures
Manufacturing crisis centralization. When a manufacturing batch fails or a supply disruption threatens clinical supply, CEOs sometimes take personal control of manufacturing operations. The appropriate CEO role in a manufacturing crisis is to ensure the right people have the authority and resources to resolve the issue, to make strategic decisions (e.g., whether to halt enrollment, how to communicate with regulators), and to communicate externally. Operational manufacturing crisis management belongs to the CTO.
Patient case escalation. Compassionate use requests from families in urgent situations can reach the CEO directly. Without a clear policy framework, these cases can consume CEO bandwidth and create inconsistent decision-making. A compassionate use policy, administered by the CMO, with escalation to the CEO only for extraordinary circumstances, is the appropriate governance model.
Regulatory novelty paralysis. When facing genuinely novel regulatory situations without clear precedent, some gene therapy CEOs become over-involved in regulatory strategy discussions, hoping that CEO presence will resolve regulatory ambiguity. In reality, regulatory ambiguity is best resolved through pre-submission scientific dialogue facilitated by expert regulatory affairs staff and CMO. The CEO’s regulatory role is strategic, not operational.
Conclusion
Gene therapy represents one of the most technically demanding and organizationally complex areas of biopharmaceuticals. The science is frontier, the regulatory environment is evolving, the manufacturing challenges are significant, and the commercial models are unprecedented. Meeting these challenges requires organizational excellence at every functional level.
Gene therapy CEOs who delegate effectively - building expert organizations with genuine authority across R&D, manufacturing, regulatory, and commercial functions - create the capacity to advance transformative therapies to patients who have no other options. That is the ultimate measure of the CEO’s effectiveness.
Related Reading
For further context, explore Delegation Strategies for Asset Management CEO and Delegation Strategies for Automotive CEO: Digital Retail.